CEO Executive AssistantLife science real estate CEO time management requires executives to operate across a set of technical, financial, and relationship dimensions that have few parallels in other real estate sectors. The CEO of a life science real estate platform is simultaneously managing relationships with biotech and pharmaceutical tenants whose space requirements are technically complex and whose credit profiles are often non-standard, overseeing wet lab and research infrastructure investments that require specialized technical knowledge, navigating capital markets that price life science assets differently from conventional real estate, and maintaining proximity to the university and research institution relationships that drive long-term tenant pipeline.
The sector’s growth over the past decade has attracted substantial institutional capital, increasing competition for quality assets and forcing life science real estate CEOs to spend more time on capital markets and differentiation strategy than their counterparts from a decade ago. Understanding where the CEO’s personal time produces the most value, and building the operational infrastructure to support everything else, is the defining time management challenge.
The Unique Complexity of Life Science Tenant Management
Life science tenants are not like office tenants. Their space requirements evolve rapidly as their research programs advance. A startup occupying 10,000 square feet of wet lab space at Series A may need 40,000 square feet two years later if its clinical program advances. A clinical-stage company that loses an FDA approval may need to sublease space it signed for 10 years. The CEO of a life science real estate platform manages this volatility as a core operational function.
Tenant portfolio monitoring at the CEO level:
The CEO should maintain a current understanding of the research and clinical development status of the platform’s major tenants. This is not standard practice in other real estate sectors, but it is essential in life science: a tenant’s research progress or setbacks are leading indicators of their future space needs, credit standing, and renewal probability.
The CEO should require the asset management team to prepare a quarterly tenant health update that covers major tenants’ funding status (recent rounds closed, cash runway), development program milestones, and any publicly disclosed headcount changes. This update takes 30 minutes to review and provides the CEO with the market intelligence needed to anticipate lease renewal challenges and expansion opportunities 12-18 months before they become urgent.
Managing early-stage biotech tenants:
Early-stage biotechs (pre-revenue, often pre-Series B) present the most complex tenant credit challenge in any real estate sector. These companies have no revenue, no earnings, and minimal tangible assets. Their credit is entirely a function of their venture capital backing and the progress of their research programs.
The CEO must personally understand the framework for underwriting early-stage biotech credit and must review the credit underwriting for any tenant commitment above a material threshold. The specific items the CEO should review: the tenant’s current cash runway relative to the lease term and planned build-out period, the VC backing quality (Tier 1 VCs with diversified portfolios and reserves for portfolio company support versus seed-stage or local investors), the clinical or research milestone schedule relative to the lease commencement, and the availability of lab credit enhancement (security deposits, letters of credit, personal guarantees from VC sponsors) to mitigate cash runway risk.
CEOs who do not personally understand biotech credit underwriting, and who allow their leasing teams to sign early-stage tenants without adequate credit review, accumulate credit risk in their tenant base that crystallizes in the inevitable venture funding downturn.
Wet Lab Build-Out Complexity and CEO Decision Points
Wet laboratory build-outs are among the most technically complex and capital-intensive improvements in commercial real estate. A standard office-to-lab conversion or new lab construction involves: upgraded HVAC systems to manage chemical fume exhaust and biosafety requirements, enhanced structural loading for heavy lab equipment, specialized plumbing for deionized water, acid waste neutralization, and gas systems, electrical infrastructure for high-draw laboratory equipment, and biosafety level containment features where required.
The capital cost of a fully fitted wet lab is commonly $300-$600 per square foot or more, compared to $80-$120 per square foot for standard office space. The build-out period is longer, the design process requires specialist lab designers, and the construction involves subcontractors (lab equipment vendors, specialty MEP contractors) who are not part of a standard GC’s typical subcontractor base.
CEO-level decisions in lab build-out programs:
Build-out investment decision by tenant credit tier: the CEO must establish an explicit policy about the relationship between tenant credit strength and landlord contribution to lab build-out. Investing $500 per square foot in a tenant improvement allowance for an unfunded pre-seed startup is a fundamentally different risk decision than the same investment for a clinical-stage company with $200 million in cash reserves. Without a CEO-level framework, leasing teams under pressure to fill vacancy may approve build-out investment levels that are not justified by tenant credit.
Infrastructure capacity decisions: the CEO must make decisions about how much base infrastructure (HVAC capacity, structural loading, electrical service) to invest in speculatively versus tenants in hand. Over-building base infrastructure creates carrying costs on unneeded capacity; under-building it creates constraints that limit the building’s appeal to high-value lab tenants and requires expensive upgrades when leases are signed.
These decisions require the CEO to have a working understanding of lab building infrastructure, which is a specialized knowledge base that distinguishes competent life science real estate CEOs from those who rely entirely on technical advisors.
University and Research Institution Proximity Strategy
Life science clusters form around research universities, teaching hospitals, and federal research laboratories. The proximity of a real estate platform’s assets to these anchors is among the most important determinants of long-term tenant pipeline quality.
CEO time investment in institutional relationships:
The CEO of a life science real estate platform should maintain direct relationships with the technology transfer offices, venture development offices, and facilities planning offices of the major research institutions in each market where the platform operates. These relationships are a source of early-stage company referrals, collaboration opportunities on research campus development, and intelligence about where institutional research activity is expanding.
These are relationships that cannot be delegated to the leasing team. The institutional contacts at research universities make referral decisions based on their confidence in the platform’s commitment to the life science mission, not just its ability to provide square footage. CEO-level engagement communicates that commitment in a way that leasing director engagement does not.
The CEO should plan for at least one substantive engagement per year with the leadership of each anchor research institution in the platform’s key markets: a campus visit, a joint event, a conference panel discussion, or a sponsored research initiative. These engagements take time but build the institutional relationships that generate long-term tenant pipeline.
JLABS and Pfizer incubator dynamics:
Pharmaceutical company-sponsored incubators (JLABS, Pfizer’s CTI Center) operate in many life science clusters and serve as both potential tenants and potential competition for early-stage biotech tenants. The CEO should understand the incubator landscape in each market and maintain relationships with incubator program directors, who are valuable sources of intelligence about graduation companies that may need their first independent lab space.
Specialized Capital Markets for Life Science Assets
Life science real estate trades at valuations and cap rates that reflect both the property’s physical characteristics and the perceived durability of life science cluster dynamics. Life science assets in Tier 1 clusters (Boston/Cambridge, San Francisco Bay Area, San Diego, Research Triangle) have historically traded at premium valuations reflecting strong tenant demand and limited supply. Assets in emerging clusters trade with a significant discount that reflects higher execution risk.
CEO-level capital markets responsibilities:
The CEO must maintain direct relationships with the life science-focused investment banking and brokerage teams at the major real estate capital markets firms. These relationships provide deal flow for acquisitions, market intelligence on cap rate trends, and when the time comes to dispose of assets, access to the buyer pool with specific interest in life science real estate.
Life science REITs (Alexandria Real Estate Equities, Healthpeak, Biomed Realty) set the public market valuation benchmark for institutional life science real estate. The CEO should track these companies’ portfolio performance, capital markets activity, and market commentary as a reference point for private market valuation trends.
Finance CEO time management principles apply directly to the life science sector’s capital markets function: the CEO must maintain current intelligence on both the debt capital markets (which finance new construction and repositioning) and equity capital markets (which establish the comparative valuation for the portfolio).
The NAREIT research on healthcare and life science real estate REITs provides useful benchmarking data on public market valuations and operating metrics. CEOs can reference NAREIT’s life science and healthcare REIT data for current sector performance context.
Tenant Credit Underwriting for Pre-Revenue Biotechs
Pre-revenue biotech tenants represent the highest-risk and highest-growth segment of the life science tenant base. Managing the CEO’s time investment in credit underwriting for this tenant segment is a specific challenge because the underwriting process is fundamentally different from conventional commercial real estate credit analysis.
A CEO’s framework for pre-revenue biotech credit review:
Stage of development: Phase 1/2 clinical companies have different risk profiles than preclinical companies. The clinical stage reflects milestone achievement and increases the probability of continued funding.
Venture backing quality: top-tier VCs (Flagship Pioneering, Third Rock Ventures, Andreessen Horowitz Bio) have historically maintained portfolio support through difficult venture markets. The ability to distinguish between VC tiers is a CEO-level judgment that requires current market knowledge.
Cash runway versus lease obligation: the CEO should require that every pre-revenue biotech lease include a stress analysis that shows the relationship between the tenant’s cash runway at lease commencement and the total lease obligation. A tenant with 18 months of cash runway signing a 7-year lease with a $5 million TI commitment is a very different credit risk from the same tenant with 48 months of cash runway.
Science quality: while the CEO is not a scientist, maintaining enough literacy in the tenant’s research field to understand whether the science is credible is a valuable complement to financial credit analysis. Many life science real estate CEOs maintain relationships with scientific advisory networks or former pharmaceutical executives who can provide a quick science quality assessment for key prospective tenants.
Lab Infrastructure Investment Decisions
The CEO of a life science real estate platform makes a series of capital investment decisions throughout the portfolio lifecycle that have long-term consequences for asset quality and tenant mix.
Speculative lab infrastructure investment:
Building spec lab space (fitted to wet lab standard before a tenant is in hand) in a strong life science cluster has historically produced good outcomes: spec lab space leases faster and at higher rents than vanilla office space in demand-constrained markets. In oversupplied markets or emerging clusters with unproven tenant demand, spec lab investment can produce significant carrying costs.
The CEO must make the spec investment decision with a clear view of market supply and demand dynamics, including the pipeline of competitive lab supply under development and the current availability of research-funded tenants in the market.
Building systems upgrades for existing office-to-lab conversions:
The CEO’s decision about how deeply to invest in upgrading an existing office building’s systems for lab use is among the most consequential capital allocation decisions in the platform’s lifecycle. Under-investment produces a building that cannot attract high-quality lab tenants because it lacks the infrastructure they require. Over-investment produces capital deployment that cannot be recovered in rent, reducing returns.
Real estate CEO support from an executive assistant who can manage the document coordination and technical briefing preparation for complex lab build-out programs allows the CEO to focus on the investment decisions rather than the logistics of the decision-making process.
Time Structure for Life Science Real Estate CEOs
A CEO managing a life science real estate portfolio of 1-3 million square feet across two or three markets needs a structured time allocation that balances the technical demands of the sector with the relationship and capital markets demands.
Weekly structure:
Monday: 30-minute portfolio performance and occupancy review. Wednesday: 20-minute tenant health review (escalated items from asset management team). Friday: preparation review for any upcoming investor or capital markets meetings.
Monthly structure:
60-minute tenant portfolio review covering all major tenants’ research status, funding news, and lease event horizon. 90-minute capital markets review covering acquisition pipeline, financing markets, and cap rate trends. One institutional relationship engagement (university technology transfer office, incubator program director, or research hospital facilities office).
Quarterly structure:
Investor reporting and LP communication. Lab build-out capital commitment review (all active and planned projects). Market supply/demand analysis update for each cluster market.
Conclusion
Life science real estate CEO time management requires an executive who combines capital markets sophistication with technical fluency in laboratory operations, deep understanding of the biotech and pharmaceutical industries, and the relationship skills to maintain credibility with both institutional investors and research institution partners. This is a broader skill set than most real estate CEO roles require, and the time management challenge reflects that breadth.
The executives who lead life science real estate platforms most effectively are those who invest their personal time at the highest-value intersection of these skill dimensions: personally reviewing pre-revenue biotech credit for major lease decisions, personally maintaining university and research institution relationships, personally engaging in capital markets conversations with the sector-specialist investor community, and personally making infrastructure investment decisions that determine the platform’s long-term competitive position. Everything else should be delegated to capable specialists with clear escalation protocols.
Related Reading
For further context, explore Time Management for Affordable Housing Developer CEOs and Hospitality Real Estate CEO Time Management: Hotels, Brands, and Capital Strategy.